All In Biotech

Drug Trial Radar · NCT02105129

A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523

A Phase I, Randomized, Double Blind, Placebo-controlled, Dose-escalating Study of the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of HMPL-523

Last checked: Nov 19, 2026Latest source record: Apr 28, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 118 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

118

Actual

Start

May 2014

Primary completion

Dec 2015

Study completion Dec 2015

Sponsor

Lead sponsor
Hutchison Medipharma LimitedIndustry
Sponsor type
Industry
First posted
Apr 7, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to assess the safety and tolerability of a single dose of up to 800 mg in Part A (evaluated in planned steps of 5, 20, 50, 100, 200, 300 mg under fasted conditions, followed by 300, 400, 600 and 800 mg HMPL-523 under fed conditions of a standard meal, followed by multiple doses of 200, 300, 400 and 500 mg of HMPL-523 in Part B, in healthy male volunteers. The secondary objective is to determine the pharmacokinetic profile of single (Part A) and multiple (Part B) oral doses of HMPL-523 in healthy male volunteers and to determine the preliminary effect of food (Part C)

Conditions

  • Rheumatoid Arthritis (RA)

Interventions

  • HMPL-523Drug

    HMPL-523: Oral administration with a single dose of 5, 20, 50, 100, 200 and 300 mg in Part A, followed by multiple doses of selected strength in Part B Other Name: NA

  • PlaceboDrug

    Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess number of participants with adverse events as a measure of safety and tolerability during dose escalatingTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network Limited

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.